블로그
- 항ccp양성 판정 이제 어떻게 되는건가요? [Reference] Anti-Cyclic Citrullinated Peptide Antibody Level and Risk of Rheumatoid Arthritis Development
-
항ccp양성 판정 이제 어떻게 되는건가요?
[Reference] Anti-Cyclic Citrullinated Peptide Antibody Level and Risk of Rheumatoid Arthritis Development
- [ADC Payload] CL2A-SN38 [BP-26342][CAS no. 1279680-68-0]_BroadPharm - 코아사이언스 CL2A-SN38 is a SN38 derivative with a Mal-PEG attached peptide linker, it can easily react with antibody to form an antibody-drug conjugate (ADC).
- [U.S. FDA] FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Adv (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of Tudriqev is indicated in combination with nivolumab for the treatment of adult patients with unresectable
- Paclitaxel-MVCP [620102][CAS no. 2119034-12-5]_MedKoo Biosciences - 코아사이언스 antibody-drug conjugates (ADCs) and targeted drug delivery systems for cancer research. The MC-Val-Cit-PAB linker is designed for high plasma stability and efficient intracellular release of
- Trontinemab [T80622][Cas No. 2568868-35-7]_TargetMol - 코아사이언스 Bioactivity Related Conjugates and Formulations Antigen Details Chemical Properties Antibody Information Herpes Viruses in the Baltimore Longitudinal Study of Aging: Associations With Brain Volumes, Cognitive
- Aurora™ Fluor 488 Anti-2SC antibody - 0.7mg/mL [CRB2105017_3]_Biosynth - 코아사이언스 Aurora™ Fluor 488 Anti-2SC antibody - 0.7mg/mL Cat.# CRB2105017_3 / Size: 50 ug Specification / MSDS Succination is a stable post-translational modification of cysteine residues, which modifies protein
- Anti-2SC monoclonal antibody, rabbit [CRB2005019_11]_Biosynth - 코아사이언스 Anti-2SC monoclonal antibody, rabbit Cat.# CRB2005019_11 / Size: 20 ug, 50 ug Specification Succination is a stable post-translational modification of cysteine residues, which modifies protein function or
- [2026 ASCO] ④ 사시투주맙-티루모테칸의 PD-L1 양성 NSCLC 환자 대상 임상 3상 결과 EGFR이나 ALK 변이가 없는 환자들에게는 면역항암제(PD-L1 억제제)인 '펨브롤리주맙(제품명: 키트루다)' 단독 요법 또는 항암화학요법과의 병용 치료가 표준 치료(Standard of 하지만 이번 ASCO 2026에서 차세대 항체-약물 접합체(ADC, Antibody-Drug Conjugate)인 '사시투주맙-티루모테칸(Sacituzumab Tirumotecan,
- immunocompromised, immunodeficient, immunodominant specific antigens 또는 epitopes이 strongest immune response을 야기하는 것입니다. virus의 특정 spike protein이 상당수의 antibody 선천적인 겨우 Inborn Errors of Immunity (IEI)로 명합니다.
1 페이지
다음 →